Abstract
Phase I trials are needed to identify the maximum safe dose of both inorganic and organic selenium (Se) compounds that could be used under medical supervision for patients at extremely high risk of cancer. Based on naturally occurring episodes of chronic selenosis and experience with Se supplementation trials, we recommend a range of doses for inorganic and organic Se compounds that should be investigated in a Phase I trial in order to identify the maximum tolerated dose for these compounds.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
